Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday,...
Lesaka to Host Webcast to Review Third Quarter 2025 Results JOHANNESBURG, April 08, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ:, JSE: LSK) ("Lesaka" or the "Company") today announced it will release third quarter 2025 results after the U.S. market close on May 7, 2025. Lesaka management will host a presentation webcast on May 8, 2025, on at 8:00am EDT (2:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: Participants using the webcast will be able to submit questions during the...
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the Ne...
Moody's Ratings (Moody's) upgraded Steelcase Inc.'s (Steelcase) ratings including its Corporate Family Rating (CFR) to Ba1 from Ba2, Probability of Default Rating (PDR) to Ba1-PD from Ba2-PD, and the rating on the company's senior unsecured notes due 2029 to Ba2 from Ba3. The company's speculative g...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.